Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, MISCELLANEOUS

Exactus, Inc. Will Appear on The National Business Show Today at 3PM EDT


DELRAY BEACH, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB:EXDI) (the "Company"), a farmer and manufacturer of hemp-derived phytocannabinoid products, today announced that Emiliano Aloi, President and CEO will appear on the National Business Show that will be broadcasted today at 3PM EDT to discuss its recent acquisitions and direction of the company.

The National Business Show broadcasts out of Beasley Studios in South Florida and can be heard on Super 740am, 103.9FM reaching all South Florida and Web Casted worldwide on www.wsbrradio.com and filmed live on AMP2.TV at 3PM EDT today. The show can also be viewed on You Tube after the LIVE broadcast. The interview will be conducted by show host, Mick Bazsuly. Questions can be emailed in advance to Mickespn@yahoo.com and the call in number is 888-721-0074.

To learn more about Exactus, Inc., visit the website at  www.exactushemp.com.

About Exactus:
Exactus Inc. is dedicated to introducing hemp-derived phytocannabinoid products into mainstream consumer markets. The Company has made investments in farming and has over 200 acres of CBD-rich hemp in Southwest Oregon. The Company is introducing a range of consumer brands, such as Green Goddess Extracts, Phenologie, Paradise CBD and Exactus. Hemp is a legal type of cannabis plant containing less than 0.3% THC (tetrahydrocannabinol), which is the psychoactive component of the cannabis plant. After 40 years of prohibition, the Agricultural Improvement Act of 2018, known as the 2018 Farm Bill, legalized hemp at the federal level. Hemp production will be regulated by the United States Department of Agriculture (USDA) and the states. As a result, in 2019 hemp was generally removed from the Controlled Substances Act (CSA) and enforcement by the Drug Enforcement Administration (DEA).

For more information about Exactus: www.exactusinc.com.

Investor Notice
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2018 filed with the Securities and Exchange Commission (the "SEC") on March 29, 2019, and in other periodic and current reports we file with the SEC.  If any of these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.

Safe Harbor - Forward-Looking Statements
The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company does not intend to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company Contact:

Andrew Johnson
Chief Strategy Officer
Exactus Inc.
509-999-9695
ir@exactusinc.com  

 


These press releases may also interest you

at 17:00
The "Global Remote Patient Monitoring Device Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering. The worldwide market of remote patient monitoring is anticipated to achieve a CAGR of 14.94% during the forecast period,...

at 17:00
PROSHRED® Security (PROSHRED®) will be celebrating the seventh anniversary for their annual nationwide "Shred Cancer" event on Saturday October 10, 2020 in partnership with The American Institute for Cancer Research (AICR). Community members are...

at 16:59
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Infusion Pumps Market ReportRead the full report: https://www.reportlinker.com/p05903751/?utm_source=PRN The infusion pumps market is expected to grow at a...

at 16:50
Ridgecrest Healthcare, a skilled nursing and rehabilitation center located in Phoenix, Arizona, appointed Charles Seal-Villafranca, DHA(c), MSHA, CDP, ALFM-BC, as its new Executive Directory and Administrator. Villafranca assumes all the roles,...

at 16:40
Tricida, Inc. announced that, due to public health concerns relating to the coronavirus pandemic (COVID-19) and to protect the health of its employees, directors and stockholders, its 2020 annual meeting of stockholders (the "Annual Meeting") will...

at 16:35
Pfizer Inc. announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients aged 12...



News published on 21 october 2019 at 12:05 and distributed by: